ReviewFuture medicinal chemistry2026
Molecular basis of ebselen biological activity.
Review in Future medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ebselen: A Multifaceted Organoselenium Compound With Therapeutic Potential in Liver Diseases.Oxidative medicine and cellular longevity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of enzyme inhibitors has sparked global efforts to develop new therapeutics. In this regard, ebselen, an organoselenium compound, has been recognized with promising broad biological and enzyme inhibition activities of thiol-containing protein,s, which modulate the redox equilibrium. The binding mode of ebselen with thiol-proteins, typically, is based on the formation of covalent Se-S bonds with cysteine residues by opening the isoselenazolone ring, i.e. cleaving the Se-N bond, and demonstrating diverse mechanism activities in numerous disease models. The thiol-protein target engagement with ebselen can have significant effects on viral replication, cellular signaling, inflammation, oxidative stress, apoptosis, cell differentiation, immune regulation, and neurodegenerative diseases and shows antimicrobial, detoxifying, and anticancer activities, suggesting wider therapeutic applications. Over its 40-year-long history, several molecular action of the ebselen inhibition mechanism have been proposed in biological systems. It has been involved in several clinical trials, demonstrating its effectiveness as a therapeutic agent aimed at preventing and treating numerous human diseases. Based on remarkable discoveries concerning ebselen, the review describes its reactivity, mechanisms of action, and activities against various molecular targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.